{"a":[{"_":"Fosun pays $32M to join Lilly and Novartis in fiercely competitive psoriasis market","$":{"href":"/biotech/fosun-pays-32m-join-lilly-and-novartis-fiercely-competitive-psoriasis-market","hreflang":"en"}}]}

Summary

Fosun Pharma subsidiary acquired Chinese rights to a near-approval autoimmune disease drug candidate from Junshi Biosciences for $32 million, entering the competitive psoriasis market alongside Lilly and Novartis.